Approximately one out of four individuals are estimated to have latent Mycobacterium Tuberculosis (Mtb). This means that at any time, these individuals may develop an active form of the disease and require antibiotic treatment. However, there is an emerging issue of antibiotic resistance, meaning that the treatment options available may not be effective in the treatment of this infectious disease. This video focuses on the mechanism of antibiotic resistance, and specifically resistance to rifampicin in Mtb patients. Ana Tomljenovic-Berube, an assistant professor in the McMaster School of Interdisciplinary Sciences, is interviewed in this video and provided guidance in the creation of the video.